// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Dec. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 2,200,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000.
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Dec. 13, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 2,200,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000.
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Dec. 11, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has reduced the price per unit of the Company ("Unit") in connection with the non-brokered private placement offering (the "Offering") previously announced on November 18, 2024, and has also increased the number of Units offered.
The price per Unit has been reduced from $0.07 per Unit to $0.05 per Unit. As the Company's intention to raise $1,000,000 remains unchanged, the number of Units offered has increased from 14,285,715 Units to 20,000,000 Units accordingly.
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Dec. 11, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has reduced the price per unit of the Company ("Unit") in connection with the non-brokered private placement offering (the "Offering") previously announced on November 18, 2024, and has also increased the number of Units offered.
The price per Unit has been reduced from $0.07 per Unit to $0.05 per Unit. As the Company's intention to raise $1,000,000 remains unchanged, the number of Units offered has increased from 14,285,715 Units to 20,000,000 Units accordingly.
DPX Formulations Superior to Mixing with Commonly Used Adjuvants
DPX Without Antigen Cargo Has Immune Stimulating Properties
Unique Potential for DPX in New Fields of Use
VANCOUVER, BC, Dec. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. The study demonstrates that DPX formulations with tumor-derived peptide neoantigens are highly effective vaccines to inhibit or prevent tumor growth following tumor challenges. DPX formulations were more effective than mixing with commonly used adjuvants, and DPX formulations were demonstrated to be as effective as the gold standard, bone marrow-derived dendritic cells. A highly significant result of the study is DPX formulations (with a checkpoint inhibitor) without a packaged cargo peptide appear to have meaningful immune stimulating properties on their own.
DPX Formulations Superior to Mixing with Commonly Used Adjuvants
DPX Without Antigen Cargo Has Immune Stimulating Properties
Unique Potential for DPX in New Fields of Use
VANCOUVER, BC, Dec. 5, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. The study demonstrates that DPX formulations with tumor-derived peptide neoantigens are highly effective vaccines to inhibit or prevent tumor growth following tumor challenges. DPX formulations were more effective than mixing with commonly used adjuvants, and DPX formulations were demonstrated to be as effective as the gold standard, bone marrow-derived dendritic cells. A highly significant result of the study is DPX formulations (with a checkpoint inhibitor) without a packaged cargo peptide appear to have meaningful immune stimulating properties on their own.
VANCOUVER, BC, Nov. 5, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.
VANCOUVER, BC, Nov. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.
Die Ergebnisse der Studie positionieren das Unternehmen als Zielgruppe für Segmente des über 270 Mrd. USD schweren Marktes für Arzneimittelverabreichungssysteme 1
VANCOUVER, BC, 31. Oktober 2024 /PRNewswire/ – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen") hebt Studien hervor, die zeigen, dass seine neuartige immunbildende Verabreichungsplattform DPX™ einzigartige Untergruppen von Antigen-präsentierenden Zellen („APCs") rekrutiert und aktiviert, um die Immunogenität von Antigenen voranzutreiben, und im Vergleich zu wässrigen und emulsionsbasierten Antigenverabreichungssystemen eine bessere Immunaktivierung aufweist.
Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market1
VANCOUVER, BC, Oct. 31, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights studies showing that its novel immune educating delivery platform, DPX™, recruits and activates unique subsets of antigen presenting cells ("APCs") to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems.
Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market1
VANCOUVER, BC, Oct. 31, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights studies showing that its novel immune educating delivery platform, DPX™, recruits and activates unique subsets of antigen presenting cells ("APCs") to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems.
BioVaxys invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation on the Emerging Growth Conference.
VANCOUVER, BC, Oct. 28, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief Executive Officer James Passin has been invited to present live at the Emerging Growth Conference on October 30th, 2024 at 9:40 AM EST. This live interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO in real time.
BioVaxys invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation on the Emerging Growth Conference.
VANCOUVER, BC, Oct. 28, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief Executive Officer James Passin has been invited to present live at the Emerging Growth Conference on October 30th, 2024 at 9:40 AM EST. This live interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO in real time.
VANCOUVER, BC, Oct. 11, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has entered into a marketing services agreement (the "Agreement") with Outside the Box Capital Inc. ("OTB") (address: 2202 Green Orchard Place, Oakville, ON L6H 4V4; email: jason@outsidethebox.capital; telephone: (289) 259-4455), for an anticipated period of six (6) months, commencing October 15, 2024, and ending April 15, 2025, whereby OTB will provide certain marketing and distribution services (the "Services") to the Company.
VANCOUVER, BC, Oct. 8, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company's DPX™ formulations.
Dr. Rajagopalan has a PhD in Pharmaceutical Chemistry/Physical Chemistry, with over 20 years of experience in nanoparticles formulation development for biomolecules (peptides, proteins, nucleic acids, VLPs, mAbs) delivery to treat cancer, infectious diseases and autoimmune disorders. Most recently, Dr. Rajagopalan was Senior Director of Formulation Development at IMV, Inc., where he developed DPX-based vaccines to treat breast, ovarian, bladder and hard to reach cancers; and DPX-based RSV, Anthrax, ZIKA, Ebola, Tuberculosis and SARS infectious disease vaccines, as well as VLP-encapsulated DPX vaccines to treat Malaria and RSV infections. He also developed the DPX formulations for SurMAGE and KRAS/BRAS antigens to treat bladder and colorectal cancers, and formulation technology to deliver multiple peptides (up to 25 neoantigens) in a single DPX formulation for personalized cancer treatment, and an emulsion technology to co-deliver both small molecules chemotherapeutics and antibodies together for cancer treatments. In addition, Dr. Rajagopalan established that DPX technology can be used as a thermostable platform for vaccines with the inclusion of right additives (sugars and biodegradable polymers). Dr. Rajagopalan holds multiple patents to treat cancer and infectious diseases using DPX technology for the delivery of peptides, proteins, nucleic acids and small molecules. Dr. Rajagopalan currently works for Toralgen Inc., as VP Formulation/Manufacturing and Scientific Development, overseeing the formulation development and CMC activities for the oral delivery of GLP-1 peptides and mAbs.
VANCOUVER, BC, Oct. 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company's DPX™ formulations.
Dr. Rajagopalan has a PhD in Pharmaceutical Chemistry/Physical Chemistry, with over 20 years of experience in nanoparticles formulation development for biomolecules (peptides, proteins, nucleic acids, VLPs, mAbs) delivery to treat cancer, infectious diseases and autoimmune disorders. Most recently, Dr. Rajagopalan was Senior Director of Formulation Development at IMV, Inc., where he developed DPX-based vaccines to treat breast, ovarian, bladder and hard to reach cancers; and DPX-based RSV, Anthrax, ZIKA, Ebola, Tuberculosis and SARS infectious disease vaccines, as well as VLP-encapsulated DPX vaccines to treat Malaria and RSV infections. He also developed the DPX formulations for SurMAGE and KRAS/BRAS antigens to treat bladder and colorectal cancers, and formulation technology to deliver multiple peptides (up to 25 neoantigens) in a single DPX formulation for personalized cancer treatment, and an emulsion technology to co-deliver both small molecules chemotherapeutics and antibodies together for cancer treatments. In addition, Dr. Rajagopalan established that DPX technology can be used as a thermostable platform for vaccines with the inclusion of right additives (sugars and biodegradable polymers). Dr. Rajagopalan holds multiple patents to treat cancer and infectious diseases using DPX technology for the delivery of peptides, proteins, nucleic acids and small molecules. Dr. Rajagopalan currently works for Toralgen Inc., as VP Formulation/Manufacturing and Scientific Development, overseeing the formulation development and CMC activities for the oral delivery of GLP-1 peptides and mAbs.
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Oct. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fifth tranche (the "Fifth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,500,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $225,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until October 4, 2026, being the date that is 24 months from the date of issue.
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Oct. 4, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fifth tranche (the "Fifth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,500,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $225,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until October 4, 2026, being the date that is 24 months from the date of issue.
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Sept. 24, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 3,000,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $150,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until September 23, 2026, being the date that is 24 months from the date of issue.
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, Sept. 24, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 3,000,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $150,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until September 23, 2026, being the date that is 24 months from the date of issue.
Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.
RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt.
Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.
Wir bedanken uns im Namen der Trading-Community bei den Betreibern der Handelsplätze für die Bereitstellung von Informationsdiensten.